Cochlear implantation (CI), which directly stimulates the cochlear nerves, is the most effective and widely used medical intervention for patients with severe to profound sensorineural hearing loss. The etiology of the hearing loss is speculated to have a major influence of CI outcomes, particularly in cases resulting from mutations in genes preferentially expressed in the spiral ganglion region.
Introduction
Hearing loss is one of the most common congenital or early onset sensory disorders, appearing in one out of 700 to 1000 newborns, with 50%e70% of cases attributable to genetic causes (Morton and Nance, 2006) . Inherited hearing loss demonstrates great heterogeneity and approximately one hundred genes are estimated to be involved (Hereditary hearing loss homepage; http://hereditaryhearingloss.org/).
Regarding the medical treatment of hearing loss, cochlear implantation (CI), which directly stimulates the cochlear nerves, is the most effective and widely used medical intervention for patients with severe to profound sensorineural hearing loss. However, the outcomes of CI vary among patients. Many factors, medical, educational, and environmental, are presumed to affect CI performance. With regard to the medical factors affecting CI outcomes, diagnostic age, pre-operative hearing thresholds, duration of preoperative hearing loss, implantation timing, associated mental retardation or other complex symptoms have been reported (Arti eres et al., 2009; Kasai et al., 2012; Forli et al., 2011; Iwasaki et al., 2012; Beadle et al., 2005; Calmels et al., 2004 Birman et al., 2015 .
Recent advances in genetic analysis technology using Massively Parallel DNA Sequencing have accelerated the exploration of novel genes involved in deafness (Walsh et al., 2010; Rehman et al., 2010; Brownstein et al., 2011; Schraders et al., 2011; Azaiez et al., 2015) and also have made possible the comprehensive genetic testing of all known deafness-causing genes in a shorter period (Shearer et al., 2010; Lin et al., 2012; Yan et al., 2013; Mutai et al., 2013; Usami, 2015, Nishio et al., 2015a) . As a result, it is now possible to identify the etiology of hearing loss in each patient prior to cochlear implantation. This information should be considered as an additional medical factor affecting CI outcome, because differences in the etiology of hearing loss will reflect different hearing loss mechanisms.
Recently, Eppsteiner et al. hypothesized that CI outcomes in patients with mutations in genes preferentially expressed in the spiral ganglion neurons might be worse than those of patients with an intra-cochlear etiology (Eppsteiner et al., 2012) . They also proposed a number of genes typically associated with poor CI performance (CHD7, DDP1/TMM8 alpha) and variable CI performance (MYH9, TMPRSS3, POU3F4) (Eppsteiner et al., 2012) . This hypothesis appears quite reasonable; however, our results for four TMPRSS3 cases treated with electric acoustic stimulation (EAS) revealed relatively good performance in comparison with patients with hearing loss of other etiologies (Miyagawa et al., 2013 (Miyagawa et al., , 2015 .
To elucidate the precise gene expression levels in the spiral ganglion and other parts of the cochlea, we performed lasercapture micro dissection in combination with next-generation sequencing (LMD-NGS) analysis and identified the expression levels of all known deafness-causing genes in each part of the cochlea. We selected four cochlear regions (the organ of Corti, spiral ganglion, lateral wall, and spiral limbs) for laser capture as these regions were representative of four cochlear functions (mechanoelectrical transduction, production of endolymph, production of the tectorial membrane, and signal transmission for the central nerve system) and have clear landmarks that make them easily distinguishable from other parts of the cochlea. This dataset will provide a base for more detailed analysis in order to predict CI outcomes on the basis of gene expression data.
Material and methods

Tissue dissection and RNA extraction
Eight male C57BL/6J mice aged 12 weeks (SLC, Shizuoka, Japan) were euthanized by decapitation under deep anesthesia with an intraperitoneal injection containing 75 mg/kg Ketamine (Daiichi Sankyo, Tokyo, Japan) and 32.4 mg/kg Pentobarbital Sodium (Kyoritsu, Tokyo, Japan). Inner ears were rapidly extracted from the temporal bone and transferred into RNAlater solution (Ambion ® , Life Technologies Co., Grand Island, NY). After removing the otic capsule, the cochlea was dissected. All of these dissections were performed in RNAlater solution to prevent RNA degradation.
After dissection, the cochlea samples were immersed in 10% sucrose followed by 30% sucrose in 0.1M phosphate buffer (pH7.4) for 1 h each and then embedded into OCT compound (Sakura Finetek, Tokyo, Japan) for sectioning at 14 mm using a Leica CM1900 cryostat (Leica Mannheim, Germany). Cryosections were fixed on Membrane Slide NF 1.0 PEN (Carl Zeiss, Munchen, Germany) and stained with a 1% cresyl violet acetate (SIGMA, St. Louis, MO, USA) ethanol solution. After washing with 100% ethanol on ice and subsequent drying, laser-capture micro dissection was performed using a PALM laser-capture micro dissection system (Carl Zeiss) according to the manufacturer's protocol. Eight micro sections of each of the organ of Corti (including the basement membranes), lateral wall, spiral ganglion, and spiral limbus (mainly the interdental cell region) were captured, respectively. Micro dissectioning of each part of the cochlea was performed four times using samples from different animals so that a total of 16 samples were prepared.
Total RNA samples were extracted using a QIAGEN RNeasy Micro Kit (QIAGEN, Hilden, Germany) according to the "PALM protocols for RNA handling" and "PALM protocols for RNA extraction from frozen sections" (Carl Zeiss).
Amplicon library preparation
Prior to amplicon library preparation, reverse transcription was performed using a High Capacity RNA-to-cDNA Kit (Applied Biosystems, Life Technologies, Foster City, CA, USA) according to the manufacturer's procedure with some modifications (input RNA samples were too small for standard measurement procedures such as Qubit, BioAnalyser or UV spectrometer, so equal volumes of total RNA samples extracted from laser-capture micro dissections were used as templates for reverse transcription. 
Base call and data analysis
The sequence data were processed with standard Ion Torrent Suite™ Software ver 4.2 and mapped to the mouse cDNA sequence for 123 target genes in multi-FASTA format with a Torrent Mapping Alignment Program. After the sequence mapping, the mapped read number for each gene was calculated using coverage analysis plugin software included in the Torrent Suite™ Software. The total mapped read number for each sample was converted to 1M reads and the relative value of the expression level for each gene was calculated (RPM: reads per million reads).
Microarray analysis
To obtain a whole cochlear gene expression profile, we performed cDNA microarray analysis. Total RNA samples from the whole cochlea of 4 C57BL6/J mice (12 weeks old) were prepared as described elsewhere with some modifications (in our previous report, we divided the cochlea into 3 pieces whereas we did not divide the cochlea in this study) (Yoshimura et al., 2014) . After RNA sample preparation, total RNA (25 ng each) was reverse-transcribed using a Low Input Quick Amp Whole Transcriptome Labeling Kit (Agilent Technologies, Santa Clara, CA) and labeled with T7 RNA polymerase mix and cyanine 3-CTP according to the manufacturer's instructions. Each cochlea sample was hybridized to SurePrint G3 Mouse GE 8 Â 60K Microarrays (Agilent Technologies), which were spotted with 60K probes (4 microarrays were used for each sample). Fluorescence intensities were measured with an Agilent Microarray Scanner (Agilent) using scanning protocols specific for each microarray assay. The expression data were extracted from raw microarray image files using Agilent Feature Extraction Image Analysis Software (Version 10.7.3.1). After quantification, mean fluorescence intensities of 4 microarray samples for 123 deafness causing genes were calculated as the whole cochlear gene expression level control.
Quantitative RT-PCR
To confirm the next-generation sequencing analysis results, qPCR was performed on 3 deafness genes and 2 house-keeping control genes. The TaqMan ® probe for each gene was selected from the TaqMan ® Gene Expression Assay system (https:// products.appliedbiosystems.com/ab/en/US/adirect/ab?; cmd¼ABGEK keywordSearch, Applied Biosystems). Gapdh and Actb were chosen as internal control genes. The estimated gene expression level (EL) was normalized to the internal control gene expression level and data are presented as the mean of log 2 EL.
Ethical statement
All experimental procedures were performed in accordance with the regulations for animal experimentation of Shinshu University. These experiments were approved by the Shinshu University Institutional Animal Care and Use Committee.
Results
Laser-capture micro dissection and next-generation sequencing
The organ of Corti region (including the basement membranes), lateral wall region (including the stria vascularis, spiral ligament, and spiral prominence), spiral ganglion region, and spiral limbus (mainly the interdental cell region) were each captured individually using a laser-capture micro dissection system ( Fig. 1 ) as representative regions of four respective cochlear functions. The organ of Corti is the center for mechanoelectrical transduction and many kinds of deafness-associated genes are expressed. The lateral wall region produces endolymph with a high positive potential and high concentration of Kþ ions. This region also expresses many kinds of deafness-associated genes including Gjb2, Gjb6, Slc26a4. The spiral limbus region produces tectorial membrane which comprises collagens and non-collagenous glycoproteins. The spiral ganglion functions to transduce sound signals to the central nerve system. In addition, we used these four regions of the cochlea are ideal for laser-capture micro dissection as they have clear landmarks that make them easily distinguishable from other parts of the cochlea (Fig. 1) .
The next-generation sequencing metrics in this study are summarized in Supplemental Table 1 (Table S1 ). From the one Ion Proton sequencing run, we obtained 43M reads with a mean read for each sample of 5.4 ± 6.3 M reads (range, 1.2M-21M reads). To normalize the differences between the samples, we converted the total mapped read number of each sample into 1M reads and calculated the relative expression level for each gene (RPM: reads per million reads).
Gene expression profiles of the whole cochlea samples
The gene expression level results of each part of the cochlea analyzed by LMD-NGS and those of the whole cochlea samples analyzed by cDNA micro array are summarized in Table 1 . Among the 123 deafness genes, Ceacam16 showed the highest fluorescence intensities in the cDNA microarray analysis of the whole cochlea samples, followed by Coch, Gjb6, Actg1, Gjb2, Slc26a4, Kcnj10, Cib2, Esrrb, and Col9a2.
To obtain a summary of LMD-NGS data reliability, we compared the averaged gene expression levels of the 4 parts of the cochlea (organ of Corti, lateral wall, spiral ganglion, and spiral limbus) obtained from the LMD-NGS analysis to those obtained from the cDNA micro array analysis of whole cochlea samples.
The gene expression levels for Ceacam16, Coch, Gjb6, Actg1, Gjb2, Esrrb, and Slc26a4 also showed high expression levels in the LMD-NGS results. However, the gene expression levels of Espn, Kcne1, and Kcnq1 differed markedly between the cDNA micro array data and the LMD-NGS data (100-fold or more differences were observed in the relative gene expression levels. Table S2 ). These inconsistencies can, perhaps, be explained by the effects of pseudogenes and/or other similar transcripts of these genes, or by mutations in the AmpliSeq primer regions. We, therefore, removed these three genes for further analysis and re-normalized the gene expression levels of each sample.
Gene expression profiles of each cochlear region
Recently we reviewed previously reported deafness gene expression patterns or encoded protein localization in the cochlea as analyzed by in situ hybridization, immunofluorescence labeling, immunohistochemistry, or reporter gene assay (Nishio et al., 2015b) . At first, we compared the gene expression profiles from the LMD-NGS to the previously reports, particularly for the welldocumented and well-established genes. GJB2, which encodes gap-junction protein connexin 26, is abundantly expressed in the cochlea, and was mainly distributed in the pillar cells, supporting cells, Hensen's cells, Claudius' cells, external sulcus cells, spiral prominence, spiral ligament, interdental cells, spiral limbus, and inner sulcus cells (Lautermann et al., 1998; Xia et al., 1999; Suzuki et al., 2003) . In the LMD-NGS results, Gjb2 gene expression showed 17,475 reads for the organ of Corti, 20,811 reads for the lateral wall, 10,369 reads for the spiral limbus, and 103 reads for the spiral ganglion. The COCH gene, which encodes the cochlin protein, is one of the most abundantly expressed proteins in the cochlea, and was mainly observed in the external sulcus cells, spiral ligament, and spiral limbus of the cochlea (Robertson et al., 2001 (Robertson et al., , 2006 . The LMD-NGS results for Coch gene expression, showed 57,176 reads for the organ of Corti, 442,265 reads for the lateral wall, 398,098 reads for the spiral limbus, and 7470 reads for the spiral ganglion. SLC26A4, which encodes the pendrin protein, was predominantly expressed in the spiral prominence region on the lateral wall and was also observed in the inner sulcus cells and interdental cells of the spiral limbus (Wangemann et al., 2004; Yoshino et al., 2004 Yoshino et al., , 2006 . Slc26a4 gene expression showed 346 reads for the organ of Corti, 40,450 reads for the lateral wall, 39,878 reads for the spiral limbus, and 2628 reads for the spiral ganglion. All of these results were consistent with those of previous reports.
Comparison of gene expression levels in the organ of Corti, lateral wall, spiral ganglion, and spiral limbus
Among the 120 genes examined, Clic5, Dfnb59, Gpsm2, Ids, Lhfpl5, and Sall1 indicated 10-fold or more higher gene expression levels in the organ of Corti in comparison with the averaged gene expression level of the other 3 parts of the cochlea (these differences were not significant, Fig. 2 ). In the lateral wall, Gjb6, Pou3f4 and Vlgr1were highly expressed at 10-fold or more than the averaged levels in the other regions (not significant). Ccdc50, Elmod3, Idua, Ildr1, Kcnj10, and P2rx2 were highly expressed in the spiral limbus, and Adcy1, Cib2, Clpp, Clrn1, Hars2, Hsd17b4, Lars2, Lrtomt, Marveld2, Rdx, Sema3e, Serpinb6, Snai2, Syne4, and Tbc1d24 were predominantly expressed in the spiral ganglion neurons (not significant).
To obtain reliable gene lists that characterized each part of the cochlea, we performed statistical analysis to compare the gene expression level for each part compared to the averaged gene expression levels for the other 3 regions of the cochlea (t-test: indicated in Table 1 ). As a result, the levels of Coch, Col11a2, and Slc26a4 gene expression in the organ of Corti were signify lower than those in the other parts of the cochlea. In the lateral wall, the Coch gene expression level was significantly higher than those in the other parts of the cochlea, while the gene expression levels of Ceacam16, and Slc26a5 were significantly lower. In the spiral limbus, the Slc26a4 expression level was significantly higher, whereas those for Atp6v1b1, Bsnd, Chd7, Col4a6, Col9a1, Col9a3, Edn3, Grxcr2, Kal, Loxhd1, Msrb3, Myo3a, Otof, Pax3, Pnpt1, Sans, Slc26a5, Smpx, Strc, Tecta, Tmc1, Triobp, Ush2a, and Whrn were significantly lower than the expression levels in the other parts of the cochlea. In the spiral ganglion, the Ush2a expression level was significantly higher, whereas those for Ceacam16, Cemip, Coch, Col11a2, Col9a2, Gjb2, Myh14, Slc26a4, and Tmprss3 were significantly lower than the levels in the other parts of the cochlea. With regard to the previously proposed deafness genes suspected of an association with poor or variable CI performance (Eppsteiner et al., 2012) , Chd7 was mainly expressed in the organ of Corti and spiral ganglion neurons, with gene expression levels of 305 reads for the organ of Corti, 97 reads for the lateral wall, 34 reads for the spiral limbus, and 178 reads for the spiral ganglion. Tmprss3 gene expression was mainly observed in the organ of Corti and lateral wall, with gene expression levels of 18,067 reads for the organ of Corti, 9323 reads for the lateral wall, 15,296 reads for the spiral limbus, and 170 reads for the spiral ganglion. Myh9 was predominantly observed in the spiral limbus, with gene expression levels of 123 reads for the organ of Corti, 6106 reads for the lateral wall, 9714 reads for the spiral limbus and 125 reads for the spiral ganglion. Pou3f4 was predominantly expressed in the lateral wall, with gene expression levels of 26 reads for the organ of Corti, 27,389 reads for the lateral wall, 2582 reads for the spiral limbus and 72 reads for the spiral ganglion.
Quantitative RT-PCR (qRT-PCR) confirms the LMD-NGS data
To confirm the LMD-NGS data, qRT-PCR was performed for 5 selected genes. Usual quantitative RT-PCR experiments begin with an equal amount of RNA samples; however, the laser-capture micro dissection samples were too small and RNA was extracted in quantities much too small for normal measurement, so we directly performed qRT-PCR and calculated the relative expression levels. Among the 5 selected genes, 3 were deafness genes (Slc26a4, Tmprss3, and Clrn1) and two were internal controls (Actb, and Gapdh). Slc26a4 gene expression was abundant in the lateral wall and spiral limbus, but only slight in the spiral ganglion and not detected in the organ of Corti as the RNA samples extracted from the organ of Corti were too small for the measurement of the Slc26a4 gene expression level by qRT-PCR. The gene expression level of Tmprss3 was higher in the organ of Corti and spiral limbus than in the lateral wall and spiral ganglion. Tmprss3 gene expression was measurable in all four parts of the cochlea. With regard to the Clrn1 gene expression level, only the spiral ganglion samples were at a measurable level and the gene was not detected in the other parts. All of the qRT-PCR data were comparable to the LMD-NGS results (Fig. 3) . 
Discussion
In this study, we revealed the detailed expression levels of deafness-associated genes in each part of the cochlea. This data set can be utilized as a tool for more detailed gene analysis of the biological functions of the cochlea.
Recently, Liu et al. performed transcriptome analysis of the inner and outer hair cells to obtain gene expression profiles of the inner and outer hair cells as well as to explore potential new deafness gene candidates (Liu et al., 2014) . They collected 2000 inner hair cells and 2000 outer hair cells from collagenase-treated organ of Corti explants using a pipette under a microscope and analyzed gene expression levels by cDNA microarray. They reported that Lhfpl5, Ptprq, Ceacam16, and Gjb2 were highly expressed genes in the inner hair cells. On the other hand, Lhfpl5, Slc26a5, and Ceacam16 were highly expressed genes in the outer hair cells. These results are consistent with our results for the gene expression profiles in the organ of Corti (including the inner and outer hair cells, pillar cells, supporting cells, Caudius' cells, Hensen's cells, and basement membranes) and Ceacam16, Gjb2, and Lhfpl5 also showed relatively high expression levels in organ of Corti.
Lhfpl5 encodes the tetraspan membrane protein and is mainly distributed in the inner and outer hair cells, pillar cells, supporting cells, Caudius' cells, and Hensen's cells of organ of Corti (LongoGuess et al., 2005; Shabbir et al., 2006; Xiong et al., 2012) . In our LMD-NGS results, Lhfpl5 expression was restricted to the organ of Corti, with the gene expression level of Lhfpl5 in the organ of Corti showing 7213 reads, 98 reads for the lateral wall, 45 reads for the spiral limus and 131 reads for the spiral ganglion. Ceacam16 encodes a glycoprotein that interacts with alpha-tectorin and may have a role in connecting the stereocilia with the tectorial membrane. Ceacam16 is mainly distributed in the inner and outer hair cells, pillar cells, supporting cells, interdental cells and tectorial membrane (Zheng et al., 2011; Kammerer et al., 2012) . Our results also show a similar distribution pattern, with abundant expression observed in the organ of Corti and spiral limbus but not in the lateral wall or spiral ganglion (Ceacam16 expression levels obtained from LMD-NGS and lysis were 218,148 reads for the organ of Corti, 46 reads for the lateral wall, 157,920 reads for the spiral limbus, and 583 reads for the spiral ganglion).
The most remarkable finding in this study was the identification of the gene expression profiles in the spiral ganglion and other parts of the cochlea. As mentioned in the Introduction, mutations of genes preferentially expressed in the spiral ganglion neurons may be associated with degeneration of the spiral ganglion. This etiology of spiral ganglion degeneration can result in worse CI performance than that for other etiologies (Eppsteiner et al., 2012) . The well-documented genes associated with good CI performance, such as Gjb2 and Slc26a4, were predominantly expressed in other parts of the cochlea and only small quantities were observed in the spiral ganglion in our results. Among the 120 genes analyzed in this study, Adcy1, Cib2, Clpp, Clrn1, Hars2, Hsd17b4, Lars2, Lrtomt, Marveld2, Rdx, Sema3e, Serpinb6, Snai2, Syne4, and Tbc1d24 were predominantly expressed in the spiral ganglion. Clrn1 endcodes the clarin 1 protein and its mutation causes Usher syndrome type 3. In a previous study, Clrn1 was also predominantly expressed in the inner and outer hair cells and spiral ganglion (Geng et al., 2009) . The results of our study were consistent with those of previous studies, and this may suggest an association between poor CI performance and Clrn1 mutations.
Interestingly, the expression levels of genes associated with many kinds of syndromic hearing loss were higher in the spiral ganglion than in the other parts of the cochlea, such as Clpp (28.7-fold higher than the averaged gene expression level of the other 3 parts of the cochlea), Hars2 (12.3 fold), Hsd17b4 (17.6 fold), Lars2 (18.4 fold) for Perrault syndrome, Polr1c (5.2 fold) and Polr1d (3.2 fold) for Treacher Collins syndrome, Ndp (3.0 fold) for Norrie Disease, Kal (5.1 fold) for Kallmann syndrome, Edn3 (2.1 fold) and Snai2 (11.3 fold) for Waardenburg syndrome, Col4a3 (2.5 fold) for Alport syndrome, Sema3e (14.8 fold) for CHARGE syndrome, Col9a1 (3.2 fold) for Sticker syndrome, Cdh23 (2.3 fold), Cib2 (92 fold), Clrn1 (42.7 fold), Pcdh15(3.0 fold), Ush1c (3.5 fold), Ush2a (3.9 fold), and Whrn (2.1 fold) for Usher syndrome and Wfs1 (3.0 fold) for Wolfram syndrome.
It is note worthy that Dfnb59, which encodes the pejvakin protein, was expressed in the spiral ganglion. This gene mutation causes autosomal recessive auditory neuropathy, and CI performance is expected to be limited (Delmaghani et al., 2006) . Further, the Wfs1 gene, which encodes the wolframin protein, is also predominantly expressed in the spiral ganglion region. This gene mutation is known to cause non-syndromic autosomal dominant low-frequency hearing loss, autosomal dominant hearing loss with optic atrophy and Wolfram syndrome, characterized by hearing loss, diabetes mellitus, optic atrophy and diabetes insipidus (Eiberg et al., 2006; Hogewind et al., 2010; Rigoli et al., 2011) . Based on our overall results, we speculated that the gene mutations associated with cochlea-specific functions, such as sound sensing by inner hair cells, cochlea amplification by outer hair cells, sound enhancing by the tectorial membrane and the formation of the unique composite endolymph fluid by the stria vascularis, may cause non-syndromic hearing loss. In contrast, the genes predominantly expressed in the spiral ganglion might have common gene expression patterns with other neuronal systems or other body parts, and mutations in these genes may cause syndromic-hearing loss.
Among the genes previously proposed to be associated with "poor or variable CI performance", Tmprss3 was predominantly expressed in the organ of Corti and lateral wall, but only small amounts were observed in the spiral ganglion in our LMD-NGS analysis and qRT-PCR analysis. These findings clearly indicated that hearing loss due to the TMPRSS3 gene mutation has a cochlea etiology and should have favorable CI outcomes. Indeed, our previous study showed that four TMPRSS3 patients responded favorably to electric acoustic stimulation (EAS) (Miyagawa et al., 2013 (Miyagawa et al., , 2015 .
Some limitations to the present study warrant discussion. First, we used a laser-capture micro dissection system to obtain the four regions of the cochlea, but the captured areas were determined manually each time and there may have been some variations in the capture conditions. To minimize such variations, we used four regions of the cochlea with clear landmarks that make them easily distinguishable from the other parts of the cochlea. Second, the LMD-NGS analysis used herein is quantitative, but the gene expression levels from the LMD-NGS analysis were the averages of the captured area and it is impossible to identify the precise expression position or cells within the captured area. Immunocytochemistry provides subcellular localization of proteins, and in situ hybridization provides more detailed information on which cells in the area express the proteins. Third, the gene expression level used in this study was normalized as reads per million reads (RPM) among the target genes. Thus, the accuracy of the gene expression levels with relatively low gene expression might be limited and may not be entirely accurate.
In summary, we demonstrated the deafness gene expression profiles in the organ of Corti, lateral wall, spiral limbus, and spiral ganglion in the mouse cochlea using LMD-NGS analysis. The expression profiles of these cochlear parts were mainly consistent with those of previous reports based on immunocytochemistry or in situ hybridization. However, our results provided quantitative data and were more accurate than previous imaging results. We believe that this will be useful for further investigation of gene expression in the cochlea and the analysis of gene functions as well as the prediction of CI outcomes based on each patient's specific etiology.
